Home › Funds › RICE HALL JAMES & ASSOCIATES, LLC › KNSA

RICE HALL JAMES & ASSOCIATES, LLC position in KNSA

KINIKSA PHARMACEUTICALS INTL · Health Care

RICE HALL JAMES & ASSOCIATES, LLC reported holding 466,050 shares of KNSA (KINIKSA PHARMACEUTICALS INTL) in its Q3 2026 13F filing — a position valued at US$34.8M, representing 1.84% of its reported portfolio and ranking #10 among its reported holdings. RICE HALL JAMES & ASSOCIATES, LLC has disclosed KNSA holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)466.05K sh
Reported value held$34.77M
Portfolio Weight1.84%
First reportedQ3 2023
Last changeReduce
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How RICE HALL JAMES & ASSOCIATES, LLC's KNSA position evolved

RICE HALL JAMES & ASSOCIATES, LLC first disclosed a stake in KNSA in Q3 2023 at 650,366 shares (US$11.3M). The position peaked in Q2 2026 at 624,928 shares, worth US$40.0M. Across 13 filings, RICE HALL JAMES & ASSOCIATES, LLC increased the stake 5 time(s), trimmed it 7 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 466,050 shares valued at US$34.8M — a reduction of -158,878 shares quarter over quarter.. Notable position changes include a 25% trim in Q3 2026 (shares rose 29% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 650.37K $11.30M New
Q4 2023 636.03K $11.16M Reduce
Q1 2024 618.80K $12.21M Reduce
Q2 2024 600.63K $11.21M Reduce
Q3 2024 649.63K $16.23M Add
Q4 2024 642.75K $12.71M Reduce
Q1 2025 624.54K $13.87M Reduce
Q2 2025 638.23K $17.66M Add
Q3 2025 577.82K $22.44M Reduce
Q4 2025 596.43K $24.60M Add
Q1 2026 608.42K $29.30M Add
Q2 2026 624.93K $39.96M Add
Q3 2026 466.05K $34.77M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About KNSA and 13F data

KNSA (KINIKSA PHARMACEUTICALS INTL) is a Health Care company. 49 other funds we track also report a position in KNSA — the largest reported positions include Rubric Capital Management LP (US$255.8M), BAKER BROS. ADVISORS LP (US$181.3M), TANG CAPITAL MANAGEMENT LLC (US$144.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding KNSA

All KNSA fund holders →

FAQ

How long has RICE HALL JAMES & ASSOCIATES, LLC held KNSA?

RICE HALL JAMES & ASSOCIATES, LLC has disclosed KNSA holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is RICE HALL JAMES & ASSOCIATES, LLC's current position in KNSA?

As of Q3 2026, RICE HALL JAMES & ASSOCIATES, LLC holds 466.05K shares of KNSA (KINIKSA PHARMACEUTICALS INTL), valued at $34.77M, representing 1.84% of its reported portfolio and ranking #10.

Has RICE HALL JAMES & ASSOCIATES, LLC been buying or selling KNSA?

In the latest 13F filing (Q3 2026), RICE HALL JAMES & ASSOCIATES, LLC reduced its position in KNSA. The position peaked in Q2 2026 at 624.93K shares.

Which other funds hold KNSA?

Other major institutional holders of KNSA include Rubric Capital Management LP, BAKER BROS. ADVISORS LP, TANG CAPITAL MANAGEMENT LLC, among 49 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.